Antiandrogen withdrawal syndrome with nilutamide

Urology

Volumn 49, Issue 4, 1997, Pages 632-634

  Huan, Susan D ^a   Gerridzen, Ronald G ^a   Yau, Jonathan C ^a   Stewart, David J ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL ACETATE; NILUTAMIDE;

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; CASTRATION; CLINICAL FEATURE; DRUG WITHDRAWAL; HEMATURIA; HORMONAL THERAPY; HUMAN; LYMPHADENECTOMY; MALE; NEPHRECTOMY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR REGRESSION; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0030971169     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00558-4     Document Type: Article

References (9)

1. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 11:1993;1566-1572.
2. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 150:1993;908-913.
3. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate specific antigen decline following discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med. 98:1995;412-414.
4. Small EJ, Carroll PR. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 43:1994;408-410.
5. Nieh PT. Withdrawal phenomenon with the antiandrogen Casodex. J Urol. 153:1995;1070-1073.
6. Dawson NA, McLeod DG. Dramatic PSA decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol. 153:1995;1946-1947.
7. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 14:1989;103-115.
8. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate cancer cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol. 37:1990;849.
9. Moul JW, Srivastava S, McLeod DG. Molecular implications of the antiandrogen withdrawal syndrome. Semin Oncol. 13:1995;157-163.